tbuckley/cabot-search huggingface dataset:
Impact of Autologous Dendritic Cell Immunotherapy (Arcelis™) on B Cell Subsets in HIV-1-Infected Subjects Receiving Antiretroviral Therapy
Authors: Mohamed-Rachid Boulassel, Bader Yassine-Diab, Don Healey, Charles Nicolette, Rafick-Pierre Sékaly, Jean Pierre Routy
Journal: Blood (2008)
Clinical Outcomes in Adult T Leukemia/Lymphoma: Report of 55 Cases from Peru.
Authors: Brady E. Beltrán-Gárate, Antonio A. Carrasco-Yalan, Olga M. Lopéz-Odría, Luis Riva-Gonzales, Hugo Ríos, Gloria Chumpitáz-Anchiraico, Silvia Falcón-Lisarazo, Juan Navarro-M, Fernando Hurtado de Mendoza, Jorge Castillo-Aguirre
Journal: Blood (2005)
Ex Vivo IL-2 Expansion of CB-NK Cells Promotes Synergistic LFA-1 and CD2 Engagement at the NK Cell Lytic Immune Synapse; Implications for Adoptive CB-NK Cell Therapy in Acute Myeloid Leukemia.
Authors: Dongxia Xing, Alan G. Ramsay, William Decker, Sufang Li, Simon Robinson, Hong Yang, Catherine M. Bollard, John G. Gribben, Elizabeth J. Shpall
Journal: Blood (2009)
Population Health Equity
Authors: David Kindig
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Attitudes to smoking and smoking habit among the staff of a hospital.
Journal: Thorax (1989)

Attitudes to smoking and smoking habit among the staff of a hspital SIR,-We read with great interest the paper of Drs P D 0 Davies and K Rajan (May 1989;44:378-81) concerning smoking in hospitals.We carried out a similar study among nurses working in a large Parisian teaching hospital with the same aim and a similar method.'Our response rate was 83% (n = 895).Prevalences of current smokers and ex-smokers were respectively 34% and 10% v 23% and 19% in Llandough hospital.Becker et al found rates of 22% and 23% among American nurses in 1986.2The French nurses were knowledgeable about smoking risks and most of them were in agreement with a ban on smoking in the hospital for nurses, patients, and families.Among the current smokers, 64% had stopped at least once and 55% wished to stop.Half of these said that they would like to join a special group in the hospital to help them give up smoking.
Reducing Potentially Excess Deaths from the Five Leading Causes of Death in the Rural United States
Authors: Macarena C. Garcia, Mark Faul, Greta Massetti, Cheryll C. Thomas, Yuling Hong, Ursula E. Bauer, Michael F. Iademarco
Journal: MMWR Surveillance Summaries (2017)

In 2014, the all-cause age-adjusted death rate in the United States reached a historic low of 724.6 per 100,000 population (1). However, mortality in rural (nonmetropolitan) areas of the United States has decreased at a much slower pace, resulting in a widening gap between rural mortality rates (830.5) and urban mortality rates (704.3) (1). During 1999–2014, annual age-adjusted death rates for the five leading causes of death in the United States (heart disease, cancer, unintentional injury, chronic lower respiratory disease (CLRD), and stroke) were higher in rural areas than in urban (metropolitan) areas (Figure 1). In most public health regions (Figure 2), the proportion of deaths among persons aged <80 years (U.S. average life expectancy) (2) from the five leading causes that were potentially excess deaths was higher in rural areas compared with urban areas (Figure 3). Several factors probably influence the rural-urban gap in potentially excess deaths from the five leading causes, many of which are associated with sociodemographic differences between rural and urban areas. Residents of rural areas in the United States tend to be older, poorer, and sicker than their urban counterparts (3). A higher proportion of the rural U.S. population reports limited physical activity because of chronic conditions than urban populations (4). Moreover, social circumstances and behaviors have an impact on mortality and potentially contribute to approximately half of the determining causes of potentially excess deaths (5).
Phase 1 Human Trial of Autologous Mesenchymal Stem Cell Transplantation for the Treatment of Decompensated Cirrhosis.
Authors: Kamran Alimoghaddam, Mehdi Mohamadnejad, Mohahamd Bagheri, Maryam Bashtar, Hossein Ghannati, Mandana Mohyeddin Bonab, Ardeshir Ghavamzadeh, Reza Malekzadeh
Journal: Blood (2007)
Pancreatic Cancer Complicated by Pancreatitis Demonstrated on FDG PET/CT
Authors: Grace Hennessy, Shankar Vamadevan, Han Loh, Chuong Bui, Ken Le, Robert Mansberg
Journal: Clinical Nuclear Medicine (2017)

A 73-year-old man was referred for F-FDG PET/CT study for staging of biopsy-proven pancreatic adenocarcinoma. The scan demonstrated focal intense FDG uptake in the pancreatic head, localizing the primary tumor. Additional moderate diffuse uptake was seen throughout the pancreas, suggestive of acute pancreatitis. Concurrent diagnostic CT showed diffuse pancreatic hypoenhancement consistent with edema. Serum lipase level was elevated, confirming a diagnosis of acute pancreatitis.
Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies
Authors: Michele Cavo, Pieter Sonneveld, Philippe Moreau, Joan Bladè, Hartmut Goldschmidt, Jesús F San Miguel, Michel Attal, Hervé Avet-Loiseau, Wolgang Igor Blau, Thierry Facon, Norma Gutierrez, Jean-Luc Harousseau, Bronno van der Holt, Juan Jose Lahuerta, Henk Lokhorst, Gerald Marit, Maria Luisa Martin, Giulia Marzocchi, Antonio Palumbo, Francesca Patriarca, Maria Teresa Petrucci, Laura Rosiñol, Hans Salwender, Carolina Terragna
Journal: Blood (2012)
Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management
Authors: Foyez Mahmud, Seung Woo Chung, Farzana Alam, Jeong Uk Choi, Seong Who Kim, In-San Kim, Sang Yoon Kim, Dong Soo Lee, Youngro Byun
Journal: Journal of Controlled Release (2017)
Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma.
Authors: Aziz Nazha, Rachel Cook, Dan T. Vogl, Patricia A. Mangan, Kimberly Hummel, Kathleen Cunningham, Selina Luger, David Porter, Stephen J. Schuster, Una O'Doherty, Mary Sell, Don L. Siegel, Edward A. Stadtmauer
Journal: Blood (2009)
Enteropathy-Associated T-Cell Lymphoma: a Clinical Prognostic Model to Identify High Risk Patients
Authors: Laura R de Baaij, Jolanda MW van de Water, Wieke HM Verbeek, Otto J Visser, Dirk J Kuik, Joost J Oudejans, Chris JLM Meijer, Chris JJ Mulder, Saskia AGM Cillessen
Journal: Blood (2010)
Identification of a MEF Gene Mutation in a Familial Hemophagocytic Lymphohistiocytosis Patient That Decreases MEF Transcriptional Activity.
Authors: H. Daniel Lacorazza, Serena Lopiccolo, Eric Rubenstein, Yan Liu, Juliana Nunes, Henrik Hasle, Bengt Fadeel, Kim Ericson, Jan-Inge Henter, Stephen D. Nimer
Journal: Blood (2005)
Systemic Following Intravitreal MTX Administration Prevents CNS Infiltration of Primary Intraocular Lymphoma
Authors: Hiroki Akiyama, Hiroshi Takase, Fumito Kubo, Tohru Miki, Masahide Yamamoto, Makoto Tomita, Manabu Mochizuki, Osamu Miura, Ayako Arai
Journal: Blood (2014)
Deep Sequencing the Tet2 Gene in 360 Patients with Myeloid Neoplasms Provides a Comprehensive and Quantitative Mutation Map and Reveals Low Level Mutant Clones.
Authors: Alexander E Smith, Azim M Mohamedali, Syed a Mian, Nicholas C Lea, Nigel Westwood, Austin G Kulasekararaj, Joop Gaken, Corinna Strupp, Norbert Gattermann, Ulrich Germing, Ghulam J Mufti
Journal: Blood (2009)
The offer of an HIV screen for an asymptomatic adult
Authors: Deborah Kirkham, Manpreet Bains,
Journal: BMJ (2017)

#### What you need to know

A 65 year old woman comes to you for monitoring of her thyroid function tests. Your practice is in an area where HIV prevalence is 2.5 per 1000. You wonder whether and how to offer her a HIV screening test.

### History

Offer screening to all eligible patients regardless of their risk status. This means a detailed sexual history is not routinely required.

For a screening test a single question may suffice:

“ We are in an area where HIV is fairly common, so we offer an HIV test to every new patient that registers with us/everybody admitted to hospital/everyone having a blood test. Would you like to be tested? Have you got any questions ?”

You may ask the patient if they have been tested before and if they think they may be at risk of HIV. Tailor information to …
Comparative study between St. Jude Madical and bioprosthetic valves in the right side of the heart.
Authors: Yoshito Kawachi, Munetaka Masuda, Ryuji Tominaga, Kouichi Tokunaga
Journal: Circulation (1991)

Comparative long-term performance characteristics of St. Jude Medical (SJM) and bioprosthetic valves were conducted retrospectively for patients who underwent prosthetic valve replacement in the right side of the heart from 1975 to 1988. Fifty-four patients received either SJM (n = 18) or bioprosthetic (n = 37) valves. The cumulative follow-up for SJM valves was 91 valves-years (range 3.9 to 7.2 years) and that for bioprostheses was 282 valve-years (range 1.3 to 14.8 years). Follow-up rate was 100%. The actuarial survival rate excluding hospital deaths at 5 years was 81 +/- 10% for SJM and 97 +/- 3% for bioprosthetic valve recipients (p = ns). The rates of freedom from thrombosis or anticoagulant-related hemorrhage, structural valve failure, prosthetic valve endocarditis, reoperation, and overall valve-related complications at 5 years were 72 +/- 11%, 100%, 100%, 83 +/- 9%, and 72 +/- 11% for SJM valve recipients, and 100%, 97 +/- 3%, 97 +/- 3%, 94 +/- 4%, and 94 +/- 4% for bioprosthetic valve recipients, respectively. Structural valve failure, prosthetic valve endocarditis and reoperations occurred at a similar incidence in each of the two types of prostheses. Thrombosis and overall valve-related events occurred more frequently in SJM valve recipients (5.5 +/- 2.5 vs 0%/valve-year; p less than 0.02, 6.6 +/- 2.7 vs 1.1 +/- 0.6 %/valve-year; p less than 0.03, respectively). The bioprosthetic valve which did not need warfarin anticoagulation therapy had low incidence of valve-related complications and showed good long-term durability even in the younger age group. The bioprosthetic valve was superior to the SJM valve in the right side of the heart.
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients
Authors: Matilde Y Follo, Carlo Finelli, Cristina Clissa, Sara Mongiorgi, Carla Filì, Costanza Bosi, Marilisa Quaranta, Stefania Paolini, Anna Maria Billi, Marco Gobbi, Michele Baccarani, Domenico Russo, Giovanni Martinelli, Lucia Manzoli, Lucio Cocco
Journal: Blood (2012)
Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)
Authors: Paula Cramer, Anna-Maria Fink, Raymonde Busch, Barbara Eichhorst, Clemens-Martin Wendtner, Natali Pflug, Friederike Schubert, Hartmut Döhner, Michael Rieger, Michael Kneba, Jiri Mayer, Michael Hallek, Kirsten Fischer
Journal: Blood (2011)
Post-Release Breakage Rate of Cryopreserved Cord Blood Products (CB) Shipped to 135 Transplant Centers from a Single Cord Blood Bank.
Authors: Ping Law, Brian Wang, Laura Gindy, Matt McCarter, Jerry Hernandez, Rafael Bolanos, Susanna Hwee, Joshua Chen, Albert Chen, Matt Lew, Tiffany Chow, Lawrence Petz, Robert Chow
Journal: Blood (2008)
Outcome of Infants Less Than One Year of Age with Acute Lymphoblastic Leukemia Treated with the Interfant-99 Protocol.
Authors: Rob Pieters, M. Schrappe, P. de Lorenzo, I. Hann, A. Vora, G. deRossi, A. Biondi, M. Felice, L. Hovi, F. Mechinaud, T. Szczepanski, A. Ferster, G. Janka, J. Rubnitz, L. Silverman, J. Stary, M. Campbell, G. Mann, R. Suppiah, M. Valsecchi
Journal: Blood (2006)
Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia
Authors: Pellegrino Musto, Vittorio Simeon, Giovanni D'Arena, Maria Carmen Martorelli, Maria Teresa Petrucci, Anna Levi, Nicola Cascavilla, Antonietta Pia Falcone, Francesco Di Raimondo, Maide Cavalli, Tommaso Caravita, Fortunato Morabito, Massimo Offidani, Nunzio Filardi, Francesco Nobile, Giulia Benevolo, Giuseppe Pietrantuono, Oreste Villani, Roberto Guariglia, Giovanna Mansueto, Rosa Lerose, Antonia Zonno, Valentina Santopietro, Fiorella D'Auria, Teodora Statuto, Katia Todoerti, Sara Bringhen, Francesca Gay, Paola Omedè, Antonino Neri, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2012)
Myeloid-Derived Suppressor Cells in Patients with Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Authors: Nunziatina Parrinello, Piera La Cava, Daniele Tibullo, Cesarina Giallongo, Orazio Di Bartolo, Eleonora Spina, Maide Cavalli, Luciana Schinocca, Anna Triolo, Alessandra Romano, Annalisa Chiarenza, Giuseppe A Palumbo, Francesco Di Raimondo
Journal: Blood (2009)
Identification of Sox4 As Key Oncogene in Leukemias with Mutated or Silenced C/EBPα
Authors: Hong Zhang, Min Ye, Meritxell Alberich-Jordà, Giovanni Amabile, Philipp B. Staber, Peter J. M. Valk, Ruud Delwel, Véronique Lefebvre, Constanze Bonifer, Daniel G. Tenen
Journal: Blood (2012)
Comprehensive Immune Reconstitution without Development of Graft Versus Host Disease (GvHD) Using Limited T-Cell Add Back at the Time of Unrelated Multi-Antigen Mismatched Pan-T-Cell Depleted Transplant.
Authors: Thea M. Friedman, Jack W. Hsu, Scott D. Rowley, Stuart L. Goldberg, Olga Azhipa, Jenny Zilberberg, Yevgeny Tkachuk, Robert A. Preti, Robert Korngold, Andrew L. Pecora
Journal: Blood (2005)
Four Cycles of Standard Bortezomib and Dexamethasone Produce Significant Overall Response Rates In Patients with Relapsed/Refractory Multiple Myeloma
Authors: Harsha Trivedi, Blanche Mavromatis, Usha Sree Chamarthy, Anas Al-Janadi, Vicki Gilreath, Gordan Srkalovic
Journal: Blood (2010)
Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study
Authors: Ana Villegas, B. Arrizabalaga, C. Fernández-lago, M. Mouzo, Jr Mayans, Jr Gonález-Porras, Rafael Duarte, Angel Francisco Remacha, Elisa Luño, JA Gasquet
Journal: Blood (2008)
Proteomic Analysis of Gray Platelet Syndrome by iTRAQ Labelling and Mass Spectroscopy: A Potential New Diagnostic Strategy for Platelet Disorders.
Authors: Silvia Perez-Pujol, Lorraine B. Anderson, Michael B. Martinez, LeeAnn Higgins, James G. White, Gary L. Nelsestuen, Nigel S. Key
Journal: Blood (2005)
CASPALLO: Phase I Clinical Trial of Allodepleted T Cells Transduced with Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation
Authors: Antonio Di Stasi, Siok K Tey, Yuriko Fujita, Russell Cruz, Alana Kennedy-Nasser, Caridad Martinez, Stephen M Gottschalk, Karin Straathof, Enli Liu, April Durett, Bambi J Grilley, Hao Liu, Barbara Savoldo, Yvon Eric, Teresita Lopez, Oumar Diouf, Adrian P. Gee, John Schindler, Catherine M Bollard, Robert A Krance, David M Spencer, Cliona M Rooney, Helen E Heslop, Gianpietro Dotti, Malcolm K Brenner
Journal: Blood (2010)
Deferiprone Oral Solution, An Alternative for Early Chelation Therapy In Young Children with Transfusional Iron Overload: A Preliminary Data From A 6-Month Study Period
Authors: Duantida Songdej, Nongnuch Sirachainan, Pakawan Wongwerawattanakoon, Praguywan Kadegasem, Ampaiwan Chuansumrit
Journal: Blood (2011)
RGT, a Sythetic Peptide, Selectively Inhibits Integrin αIIbβ3 Outside-In Signaling in Human Platelets through Disassociating SRC Kinase from β3 Subunit.
Authors: Xiaoyu Su, Jianqing Mi, Yuanjing Lu, Hongchen Liu, Saijuan Chen, Xiaodong Xi
Journal: Blood (2007)
Imaging the Differential Engraftment of GFP-Expressing Spleen and Bone Marrow Cells in Various Organs after Reduced-Intensity Stem Cell Transplantation in Mice Model.
Authors: Yuji Heike, Zhijian Yang, Huaiyu Ma, Robert Hoffmann, Yuriko Morita, Atsuko Soeda, Hiroaki Makiyama, Kensei Tobinai, Yoichi Takaue
Journal: Blood (2006)
Association between Soluble Klotho and Change in Kidney Function: The Health Aging and Body Composition Study
Authors: David A. Drew, Ronit Katz, Stephen Kritchevsky, Joachim Ix, Michael Shlipak, Orlando M. Gutiérrez, Anne Newman, Andy Hoofnagle, Linda Fried, Richard D. Semba, Mark Sarnak
Journal: Journal of the American Society of Nephrology (2017)

CKD appears to be a condition of soluble klotho deficiency. Despite known associations between low soluble klotho levels and conditions that promote kidney damage, such as oxidative stress and fibrosis, little information exists regarding the longitudinal association between soluble klotho levels and change in kidney function. We assayed serum soluble α -klotho in 2496 participants within the Health Aging and Body Composition study, a cohort of older adults. The associations between soluble klotho levels and decline in kidney function (relative decline: eGFR decline ≥30%; absolute decline: eGFR decline &gt;3 ml/min per year) and incident CKD (incident eGFR &lt;60 ml/min per 1.73 m 2 and &gt;1 ml/min per year decline) were evaluated. We adjusted models for demographics, baseline eGFR, urine albumin-to-creatinine ratio, comorbidity, and measures of mineral metabolism. Among participants, the mean (SD) age was 75 (3) years, 52% were women, and 38% were black. Median (25th, 75th percentiles) klotho level was 630 (477, 817) pg/ml. In fully adjusted models, each two-fold higher level of klotho associated with lower odds of decline in kidney function (odds ratio, 0.78 [95% confidence interval, 0.66 to 0.93] for 30% decline in eGFR, and 0.85 [95% confidence interval, 0.73 to 0.98] for &gt;3 ml/min per year decline in eGFR), but not of incident CKD (incident rate ratio, 0.90 [95% confidence interval, 0.78 to 1.04]). Overall, a higher soluble klotho level independently associated with a lower risk of decline in kidney function. Future studies should attempt to replicate these results in other cohorts and evaluate the underlying mechanism.
Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers
Authors: Francesco Zaja, Stefano De Luca, Umberto Vitolo, Lorella Orsucci, Alessandro Levis, Flavia Salvi, Chiara Rusconi, Erika Ravelli, Alessandra Tucci, Chiara Bottelli, Monica Balzarotti, Armando Santoro, Ercole Brusamolino, Maurizio Bonfichi, Alice Di Rocco, Caterina Stelitano, Luca Baldini, Stefano A. Pileri, Stefano Volpetti, Fabio Saccona, Gianni Ciccone, Antonella Ferranti, Ivana Catacchio, Roberto Ria, Angelo Vacca, Renato Fanin
Journal: Blood (2010)
Significant Reduction of BCR-ABL Transcripts after Switching to Imatinib Therapy in Patients with CML and Complete or Near-Complete Cytogenetic Responses to Interferon-Alpha (IFN).
Authors: Susan Branford, Timothy Hughes, Steven Stylian, Anthony P. Schwarer, Chris Arthur, Robin Filshie, Susan Moreton, Robyn Rodwell, Nancy Guzzo-Pernell, Deb Taylor, Jenny Larson, Rachel Koelmayer, Alvin Milner, Kevin Lynch, Kerry McDonald Taylor
Journal: Blood (2006)
Implementing medical revalidation in the United Kingdom: Findings about organisational changes and impacts from a survey of Responsible Officers
Authors: Kieran Walshe, Alan Boyd, Marie Bryce, Kayleigh Luscombe, Abigail Tazzyman, John Tredinnick-Rowe, Julian Archer
Journal: Journal of the Royal Society of Medicine (2017)

Objective To describe the implementation of medical revalidation in healthcare organisations in the United Kingdom and to examine reported changes and impacts on the quality of care. Design A cross-sectional online survey gathering both quantitative and qualitative data about structures and processes for medical revalidation and wider quality management in the organisations which employ or contract with doctors (termed ‘designated bodies’) from the senior doctor in each organisation with statutory responsibility for medical revalidation (termed the ‘Responsible Officer’). Setting United Kingdom Participants Responsible Officers in designated bodies in the United Kingdom. Five hundred and ninety-five survey invitations were sent and 374 completed surveys were returned (63%). Main outcome measures The role of Responsible Officers, the development of organisational mechanisms for quality assurance or improvement, decision-making on revalidation recommendations, impact of revalidation and mechanisms for quality assurance or improvement on clinical practice and suggested improvements to revalidation arrangements. Results Responsible Officers report that revalidation has had some impacts on the way medical performance is assured and improved, particularly strengthening appraisal and oversight of quality within organisations and having some impact on clinical practice. They suggest changes to make revalidation less ‘one size fits all’ and more responsive to individual, organisational and professional contexts. Conclusions Revalidation appears primarily to have improved systems for quality improvement and the management of poor performance to date. There is more to be done to ensure it produces wider benefits, particularly in relation to doctors who already perform well.
Efficacy of Alphanate® (Human Factor VIII/Von Willebrand Factor Concentrate) in Preventing Excessive Bleeding during Surgery or Invasive Procedures in Patients with Congenital Von Willebrand Disease. A Multicenter Retrospective Study.
Authors: M. Elaine Eyster, Charles L. Sexauer, Simon Brown, Richard A. Lipton, Craig M. Kessler, Louis M. Aledort, Georges E. Rivard
Journal: Blood (2005)